Classes
DEA Class; Rx
Common Brand Names; Travatan, Travatan Z
- Antiglaucoma, Prostaglandin Agonists
Description
Topical ophthalmic agent; prodrug used to lower IOP in patients with open-angle glaucoma or ocular hypertension; synthetic analog of prostaglandin F2alpha; this drug is associated with iridal brown pigmentation similar to latanoprost.
Indications
Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
Adverse Effects
- Increased pigmentation of iris & periorbital tissue & increased pigmentation, thickening, elongation & growth of eyelashes (59%)
- Ocular hyperemia (35-50%)
- Decreased visual acuity (5-10%)
- Ocular discomfort (5-10%)
- Foreign body sensation (5-10%)
- Pain (5-10%)
- Pruritus (5-10%)
- Abnormal vision (1-4%)
- Blepharitis (1-4%)
- Blurred vision (1-4%)
- Cataract (1-4%)
- Conjunctivitis (1-4%)
- Dry eye (1-4%)
- Iris discoloration (1-4%)
- Keratitis (1-4%)
- Lid margin crusting (1-4%)
- Photophobia (1-4%)
- Subconjunctival hemorrhage (1-4%)
- Tearing (1-4%)
Warnings
Treatment may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, and number of lashes; eyelash changes are usually reversible upon discontinuation of treatment
Treatment should be used with caution in patients with active intraocular inflammation (eg, uveitis) because inflammation may be exacerbated
Macular edema, including cystoid macular edema, reported during treatment with travoprost ophthalmic solution; this drug should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
This drug has not been evaluated for treatment of angle-closure, inflammatory or neovascular glaucoma
There have been reports of bacterial keratitis associated with use of multiple-dose containers of topical ophthalmic products; these containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface
Contact lenses should be removed prior to instillation of the drug and may be reinserted 15 minutes following its administration
Pregnancy and Lactation
There are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk; advise pregnant women of a potential risk to a fetus
There are no data on effects on breastfed child or milk production; it is not known if drug is present in human milk following ophthalmic administration
Maximum Dosage
1 drop/day per affected eye.
1 drop/day per affected eye.
16 to 17 years: 1 drop/day per affected eye.
13 to 15 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
